Ş. Dede, M. Şahpolat, M. H. Kokacya, M. Ari, Cem Sesliokuyucu, Z. Yonden
Serum apelin and nesfatin-1 levels in depression patients and their relationship with treatment Objective: This study was designed to investigate the molecules apelin and nesfatin-1, their relationship with depression before and after treatment, and whether they can be used as biomarkers. Method: Forty-seven depression patients referred to psychiatric outpatient clinic who were not on treatment and 47 normal healthy volunteers were enrolled in the study. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), the Hamilton Depression Rating Scale (HAM-D), and the Clinical Global Impression (CGI) Scale were administered to all participants. Peripheral blood samples were collected following a 12-hour fasting at the beginning and three months after the start of treatment. Serum apelin and nesfatin-1 levels were measured. Results: Of the 47 depression patients, 35 (74.5%) were females and 12 (25.5%) were males. Thirty-one (66%) of the 47 volunteers were females and 16 (34%) of them were males. Age, marital status, occupation and Body Mass Index (BMI) did not differ between the groups. Serum apelin level was significantly higher in the patient group than in the control group. There was no significant difference between the patient group and the control group in terms of serum nesfatin-1 levels. There was no significant difference in serum apelin and serum nesfatin-1 levels after 3 months of treatment. Conclusions: Serum apelin levels were significantly higher than healthy controls at the time of admission and there was no change in apelin levels after 3-months of treatment (antidepressant, antidepressant + electroconvulsive therapy, antidepressant + therapy) despite clinical recovery. Serum nesfatin-1 levels in the patient group were not different from the control group at the time of referral and at the end of 3 months treatment. There was no relationship between serum apelin level and BMI in our study. Serum nesfatin-1 level and BMI were correlated at the time of admission.
{"title":"Serum Apelin And Nesfatin-1 Levels in Depression Patients and Their Relationship with Treatment","authors":"Ş. Dede, M. Şahpolat, M. H. Kokacya, M. Ari, Cem Sesliokuyucu, Z. Yonden","doi":"10.5350/DAJPN2017300105","DOIUrl":"https://doi.org/10.5350/DAJPN2017300105","url":null,"abstract":"Serum apelin and nesfatin-1 levels in depression patients and their relationship with treatment Objective: This study was designed to investigate the molecules apelin and nesfatin-1, their relationship with depression before and after treatment, and whether they can be used as biomarkers. Method: Forty-seven depression patients referred to psychiatric outpatient clinic who were not on treatment and 47 normal healthy volunteers were enrolled in the study. The Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), the Hamilton Depression Rating Scale (HAM-D), and the Clinical Global Impression (CGI) Scale were administered to all participants. Peripheral blood samples were collected following a 12-hour fasting at the beginning and three months after the start of treatment. Serum apelin and nesfatin-1 levels were measured. Results: Of the 47 depression patients, 35 (74.5%) were females and 12 (25.5%) were males. Thirty-one (66%) of the 47 volunteers were females and 16 (34%) of them were males. Age, marital status, occupation and Body Mass Index (BMI) did not differ between the groups. Serum apelin level was significantly higher in the patient group than in the control group. There was no significant difference between the patient group and the control group in terms of serum nesfatin-1 levels. There was no significant difference in serum apelin and serum nesfatin-1 levels after 3 months of treatment. Conclusions: Serum apelin levels were significantly higher than healthy controls at the time of admission and there was no change in apelin levels after 3-months of treatment (antidepressant, antidepressant + electroconvulsive therapy, antidepressant + therapy) despite clinical recovery. Serum nesfatin-1 levels in the patient group were not different from the control group at the time of referral and at the end of 3 months treatment. There was no relationship between serum apelin level and BMI in our study. Serum nesfatin-1 level and BMI were correlated at the time of admission.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"375 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122775879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures. Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels. Thus, the release of excitatory neuro-transmitters are inhibited and neuronal GABA levels are increased. Pregabalin has also been approved in the European Union for treatment of Generalized Anxiety Disorder. The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration. However, the Food and Drug Administration in the USA (FDA) and European Medicines Agency (EMA) have included pregabalin in the “Schedule V Controlled Substances”. This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse.
{"title":"Pregabalin Addiction in a Case with Synthetic Cannabinoid Use","authors":"G. Koroglu","doi":"10.5350/DAJPN2017300108","DOIUrl":"https://doi.org/10.5350/DAJPN2017300108","url":null,"abstract":"Pregabalin addiction in a case with synthetic cannabinoid use Pregabalin is a gamma-aminobutyric acid (GABA) analog that is approved for the treatment of neuropathic pain and partial-onset seizures. Pregabalin selectively binds to the alpha 2 delta subunit of voltage-gated calcium channels. Thus, the release of excitatory neuro-transmitters are inhibited and neuronal GABA levels are increased. Pregabalin has also been approved in the European Union for treatment of Generalized Anxiety Disorder. The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration. However, the Food and Drug Administration in the USA (FDA) and European Medicines Agency (EMA) have included pregabalin in the “Schedule V Controlled Substances”. This means that just like the benzodiazepines, pregabalin is considered to be a drug with a low potential for abuse.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122930050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The aim of the present study was to evaluate the effect of post-traumatic stress disorder (PTSD) symptoms measured with the PTSD Checklist Civilian (PCL-C) version on the severity of alcohol-related problems while controlling for the effects of anxiety and depression in a sample of inpatients with alcohol use disorder (AUD). Method: Participants (n=190) were evaluated with the Beck Depression Inventory (BDI), the State-Trait Anxiety Inventory State Subscale (STAI-S), the PTSD Checklist Civilian (PCL-C) Version and the Michigan Alcohol Screening Test (MAST). Results: Although severity of the state of anxiety predicted the severity of alcohol-related problems in the first and depression in the second step of a linear regression model, when severity of PTSD symptoms was included in the analysis, it was the only independent variable that predicted the severity of alcohol-related problems while the state of anxiety and depression were no longer predictors. Conclusion: These findings suggest that the severity of PTSD symptoms is related to the severity of alcohol-related problems, independent from severity of state anxiety and depression among inpatients with AUD.
{"title":"Severity of PTSD Symptoms and Its Relationship with Severity of Alcohol-Related Problems in a Sample of Inpatients with Alcohol use Disorder","authors":"C. Evren, G. Umut, B. Evren","doi":"10.5350/DAJPN2017300103","DOIUrl":"https://doi.org/10.5350/DAJPN2017300103","url":null,"abstract":"Objective: The aim of the present study was to evaluate the effect of post-traumatic stress disorder (PTSD) symptoms measured with the PTSD Checklist Civilian (PCL-C) version on the severity of alcohol-related problems while controlling for the effects of anxiety and depression in a sample of inpatients with alcohol use disorder (AUD). \u0000Method: Participants (n=190) were evaluated with the Beck Depression Inventory (BDI), the State-Trait Anxiety Inventory State Subscale (STAI-S), the PTSD Checklist Civilian (PCL-C) Version and the Michigan Alcohol Screening Test (MAST). \u0000Results: Although severity of the state of anxiety predicted the severity of alcohol-related problems in the first and depression in the second step of a linear regression model, when severity of PTSD symptoms was included in the analysis, it was the only independent variable that predicted the severity of alcohol-related problems while the state of anxiety and depression were no longer predictors. \u0000Conclusion: These findings suggest that the severity of PTSD symptoms is related to the severity of alcohol-related problems, independent from severity of state anxiety and depression among inpatients with AUD.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134398184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Gamma-hydroxybutyrate (GHB): an Emerging Substance of Abuse","authors":"Ü. Özer, Mert Batmaz, I. Akbas","doi":"10.5350/DAJPN2017300111","DOIUrl":"https://doi.org/10.5350/DAJPN2017300111","url":null,"abstract":"","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128060128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
F. İzci, Ebru Fındıklı, S. Zincir, Akif Camkurt, Ozlem Kazan Kizilkurt, Ferzan Ergun Giynas, S. Korkmaz, E. B. Akin
Psychiatric evaluation of organ donor candidates in a university hospital and their anxiety, depression and quality of life levels Objective: The aim of this study was to conduct a psychiatric evaluation of organ donor candidates and to investigate their levels of anxiety, depression and quality of life. Material and Methods: This study was performed between May 2015 and February 2016. It included 102 volunteers. The socio-demographic Data Collection Form, DSM-IV Clinical Interview Form – Clinical Version Structured for Axis Diagnoses (SCID-I/CV), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Symptom Checklist (SCL-90-R), and SF-36 Quality of Life Survey (SF-36) were administered to the patients. Results: The average age of the applicants was found to be 41.64±12.02, 42.2% (n=43) being male and 57.8% (n=59) being female. When it comes to the degree of affinity between potential donors and recipients, 57.8% (n=59) were first-degree relatives, 19.6% (n=20) were spouses, and 22.5% (n=23) were other relatives and/or close relations. By dividing donor candidates into groups by the degree of their affinity to recipients, there were statistically significant differences revealed between BDI, BAI and SCL-90-R total scores and interpersonal sensitivity subscale scores. Conclusion: As compared to the global average, the number of living donors is higher than cadaver donors; and donor candidates mostly comprise spouses and first-degree relatives. Therefore, family members and first-degree relatives who are affected directly or indirectly by the transplant process are exposed to social and psychological effects more as the donor candidates/donors. It is of crucial importance to evaluate the psychosocial states of donors, in addition to recipients, in order to manage the long-lasting transplant process, a treatmentand caredemanding one in a more appropriate way.
{"title":"Psychiatric Evaluation of Organ Donor Candidates in a University Hospital and Their Anxiety, Depression and Quality of Life Levels","authors":"F. İzci, Ebru Fındıklı, S. Zincir, Akif Camkurt, Ozlem Kazan Kizilkurt, Ferzan Ergun Giynas, S. Korkmaz, E. B. Akin","doi":"10.5350/DAJPN2017300106","DOIUrl":"https://doi.org/10.5350/DAJPN2017300106","url":null,"abstract":"Psychiatric evaluation of organ donor candidates in a university hospital and their anxiety, depression and quality of life levels Objective: The aim of this study was to conduct a psychiatric evaluation of organ donor candidates and to investigate their levels of anxiety, depression and quality of life. Material and Methods: This study was performed between May 2015 and February 2016. It included 102 volunteers. The socio-demographic Data Collection Form, DSM-IV Clinical Interview Form – Clinical Version Structured for Axis Diagnoses (SCID-I/CV), Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI), Symptom Checklist (SCL-90-R), and SF-36 Quality of Life Survey (SF-36) were administered to the patients. Results: The average age of the applicants was found to be 41.64±12.02, 42.2% (n=43) being male and 57.8% (n=59) being female. When it comes to the degree of affinity between potential donors and recipients, 57.8% (n=59) were first-degree relatives, 19.6% (n=20) were spouses, and 22.5% (n=23) were other relatives and/or close relations. By dividing donor candidates into groups by the degree of their affinity to recipients, there were statistically significant differences revealed between BDI, BAI and SCL-90-R total scores and interpersonal sensitivity subscale scores. Conclusion: As compared to the global average, the number of living donors is higher than cadaver donors; and donor candidates mostly comprise spouses and first-degree relatives. Therefore, family members and first-degree relatives who are affected directly or indirectly by the transplant process are exposed to social and psychological effects more as the donor candidates/donors. It is of crucial importance to evaluate the psychosocial states of donors, in addition to recipients, in order to manage the long-lasting transplant process, a treatmentand caredemanding one in a more appropriate way.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117239873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Kara, M. N. Kalem, H. Balci, Z. Kalem, E. Yüce, Z. C. I. Duvan
Objective: Hyperemesis gravidarum (HG) is a condition with severe nausea and vomiting, which is seen in 0.3-2% of pregnancies. In addition to biological factors, psychosocial factors were also reported to play a role in the development of HG. However, the impact of psychosocial factors in HG has not been elucidated yet. In this research, we aimed to investigate psychiatric symptoms in patients with HG and their relationships with perceived social support, coping styles, and dyadic adjustment. Method: Forty-eight women with HG hospitalized in the Obstetrics and Gynecology Inpatient Unit and 48 healthy pregnant women consulted to the Obstetric Outpatient Unit for their routine obstetric control were recruited for the study. The subjects were evaluated with sociodemographic form, Symptom Check List (SCL-90-R), Multidimensional Scale of Perceived Social Support (MSPSS), Ways of Coping Scale (WCS), and Dyadic Adjustment Scale (DAS). Results: All sociodemographic variables except nausea and vomiting history in previous pregnancies were similar in both groups. All subscales and global symptom index scores of SCL-90-R were higher; optimistic and submissive subscale scores of WCS were lower, satisfaction, consensus and total scores of DAS were higher in HG group (p
{"title":"Psychiatric symptoms, perceived social support, coping styles, and dyadic adjustment in pregnant women with hyperemesis gravidarum","authors":"N. Kara, M. N. Kalem, H. Balci, Z. Kalem, E. Yüce, Z. C. I. Duvan","doi":"10.5350/DAJPN2016290402","DOIUrl":"https://doi.org/10.5350/DAJPN2016290402","url":null,"abstract":"Objective: Hyperemesis gravidarum (HG) is a condition with severe nausea and vomiting, which is seen in 0.3-2% of pregnancies. In addition to biological factors, psychosocial factors were also reported to play a role in the development of HG. However, the impact of psychosocial factors in HG has not been elucidated yet. In this research, we aimed to investigate psychiatric symptoms in patients with HG and their relationships with perceived social support, coping styles, and dyadic adjustment. \u0000Method: Forty-eight women with HG hospitalized in the Obstetrics and Gynecology Inpatient Unit and 48 healthy pregnant women consulted to the Obstetric Outpatient Unit for their routine obstetric control were recruited for the study. The subjects were evaluated with sociodemographic form, Symptom Check List (SCL-90-R), Multidimensional Scale of Perceived Social Support (MSPSS), Ways of Coping Scale (WCS), and Dyadic Adjustment Scale (DAS). \u0000Results: All sociodemographic variables except nausea and vomiting history in previous pregnancies were similar in both groups. All subscales and global symptom index scores of SCL-90-R were higher; optimistic and submissive subscale scores of WCS were lower, satisfaction, consensus and total scores of DAS were higher in HG group (p","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"546 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123106859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-12-23DOI: 10.5350/DAJPN20162904001
M. Gitlin
One of the current conundrums in the psychopharmacology of bipolar disorder is usually phrased as: Why isn’t lithium prescribed more often, especially as a maintenance treatment? After all: 1) It is our oldest and most well established agent; its efficacy has been established in many studies and verified in a recent meta-analysis (1); 2) multiple Practice Guidelines from a variety of countries and regions have consistently deemed lithium as the first line, “gold standard” of mood stabilizers; 3) befitting a gold standard treatment, it is frequently utilized as an active comparator when testing new mood stabilizers (2-4); 4) since it has been prescribed for over 50 years, there is little worry that new long term toxicities or side effects will emerge; 5) equally, there is an astonishing amount of clinical experience with lithium’s use (including mine, having prescribed lithium for 40 years, during over 30 years of which I have directed an academic Mood Disorders Clinic). Despite these compelling reasons to prescribe lithium, evidence from multiple studies in both bipolar disorder and when it is used as an adjunctive antidepressant treatment demonstrate declining and/ or lower prescribing rates of lithium than would be anticipated (5-7). Frequently, this issue is reviewed with the conclusion that we should prescribe lithium more often (as in Professor Nolen’s (8) thoughtful and wise review in this Journal recently). Yet, when a phenomenon-the decreased use of lithium-is repeatedly observed, it may be wise to consider the reasons for the observation instead of simply exhorting our colleagues to act differently. In this article, despite my gratitude for the availability of, experience with, and academic interest in lithium (9), I will present the counter argument, suggesting answers to the question of why lithium is not prescribed more often.
{"title":"Why is not lithium prescribed more often? Here are the reasons","authors":"M. Gitlin","doi":"10.5350/DAJPN20162904001","DOIUrl":"https://doi.org/10.5350/DAJPN20162904001","url":null,"abstract":"One of the current conundrums in the psychopharmacology of bipolar disorder is usually phrased as: Why isn’t lithium prescribed more often, especially as a maintenance treatment? After all: 1) It is our oldest and most well established agent; its efficacy has been established in many studies and verified in a recent meta-analysis (1); 2) multiple Practice Guidelines from a variety of countries and regions have consistently deemed lithium as the first line, “gold standard” of mood stabilizers; 3) befitting a gold standard treatment, it is frequently utilized as an active comparator when testing new mood stabilizers (2-4); 4) since it has been prescribed for over 50 years, there is little worry that new long term toxicities or side effects will emerge; 5) equally, there is an astonishing amount of clinical experience with lithium’s use (including mine, having prescribed lithium for 40 years, during over 30 years of which I have directed an academic Mood Disorders Clinic). Despite these compelling reasons to prescribe lithium, evidence from multiple studies in both bipolar disorder and when it is used as an adjunctive antidepressant treatment demonstrate declining and/ or lower prescribing rates of lithium than would be anticipated (5-7). Frequently, this issue is reviewed with the conclusion that we should prescribe lithium more often (as in Professor Nolen’s (8) thoughtful and wise review in this Journal recently). Yet, when a phenomenon-the decreased use of lithium-is repeatedly observed, it may be wise to consider the reasons for the observation instead of simply exhorting our colleagues to act differently. In this article, despite my gratitude for the availability of, experience with, and academic interest in lithium (9), I will present the counter argument, suggesting answers to the question of why lithium is not prescribed more often.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"91 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126184068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mania induced by aripiprazole use: a case presentation Olanzapine, quetiapine and aripiprazole have been shown to be effective treatments for bipolar depression. However, induction of manic and depressive episodes with atypical antipsychotic treatments have also been described as risk. Current literature described antidepressant effects of Aripiprazole with the risk of manic shift. In this report, a case who developed manic episode with the treatment of 30mg/day of the aripiprazole will be discussed. A 35-year-old, woman, who had 12 years history of bipolar affective disorder-I (BAD-I) for 12 years, and taking paliperidone 9mg/day and lithium 1200mg/day for the last 14 months. She was admitted to outpatient clinic by her parents with complaints of fatigue, loss of pleasure and increased sleep. She was suspicious, had thoughts of getting harm form others and being a sinner, and suspecting that someone put a spell on her. She was admitted to inpatient service with the diagnosis of BAD-I depressive episode with psychotic features. Aripiprazole 30mg/day was added to current treatment regime. Consequently, increase in targeted activities, inappropriate affect, decreased need for sleep, and grandiose delusions were observed. The symptoms of mania were considered to be induced by aripiprazole, and its dose was decreased to 10mg/day. Following the dose reduction, sleepiness and her delusions were improved within the consecutive 2 weeks.
奥氮平、喹硫平和阿立哌唑已被证明是治疗双相抑郁症的有效药物。然而，用非典型抗精神病药物诱导躁狂和抑郁发作也被认为是有风险的。目前的文献描述了阿立哌唑的抗抑郁作用与躁狂转变的风险。在本报告中，将讨论一个在阿立哌唑治疗30mg/d后出现躁狂发作的病例。女性，35岁，有12年双相情感障碍- i (BAD-I)病史12年，过去14个月服用帕利哌酮9mg/天，锂1200mg/天。她被父母送进门诊，主诉疲劳、失去快乐、睡眠增加。她很多疑，想要受到别人的伤害，成为一个罪人，怀疑有人对她下了咒。她被诊断为具有精神病性特征的BAD-I型抑郁发作而住院。在当前治疗方案中添加阿立哌唑30mg/天。结果，观察到目标活动增加，不适当的影响，睡眠需求减少和浮夸妄想。考虑躁狂症症状为阿立哌唑所致，剂量降至10mg/天。减少剂量后，连续2周嗜睡和妄想均得到改善。
{"title":"Mania induced by aripiprazole use: a case presentation","authors":"Demet Sağlam Aykut, A. Tiryaki, Evrim Özkorumak","doi":"10.5350/DAJPN2016290409","DOIUrl":"https://doi.org/10.5350/DAJPN2016290409","url":null,"abstract":"Mania induced by aripiprazole use: a case presentation Olanzapine, quetiapine and aripiprazole have been shown to be effective treatments for bipolar depression. However, induction of manic and depressive episodes with atypical antipsychotic treatments have also been described as risk. Current literature described antidepressant effects of Aripiprazole with the risk of manic shift. In this report, a case who developed manic episode with the treatment of 30mg/day of the aripiprazole will be discussed. A 35-year-old, woman, who had 12 years history of bipolar affective disorder-I (BAD-I) for 12 years, and taking paliperidone 9mg/day and lithium 1200mg/day for the last 14 months. She was admitted to outpatient clinic by her parents with complaints of fatigue, loss of pleasure and increased sleep. She was suspicious, had thoughts of getting harm form others and being a sinner, and suspecting that someone put a spell on her. She was admitted to inpatient service with the diagnosis of BAD-I depressive episode with psychotic features. Aripiprazole 30mg/day was added to current treatment regime. Consequently, increase in targeted activities, inappropriate affect, decreased need for sleep, and grandiose delusions were observed. The symptoms of mania were considered to be induced by aripiprazole, and its dose was decreased to 10mg/day. Following the dose reduction, sleepiness and her delusions were improved within the consecutive 2 weeks.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124852297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A case of psychogenic movement disorder mimicking acute cerebellar syndrome Psychogenic movement disorders (PMDs) are involuntary movements of various kinds without any underlying organic etiology. They can occur as tremor, spasm, dystonia, parkinsonism or myoclonus. A detailed history and neurological examination is essential to differentiate these disorders from organic neurological etiologies. Since PMDs are challenging entities in clinical practice, we presented this case of psychogenic tremor and gait disorder mimicking acute cerebellar syndrome in order to emphasize the importance of diagnostic clinical clues of PMDs in the differentiation of organic diseases, and to give
{"title":"A case of psychogenic movement disorder mimicking acute cerebellar syndrome","authors":"Y. Değirmenci, Ayhan Ozturk","doi":"10.5350/DAJPN2016290408","DOIUrl":"https://doi.org/10.5350/DAJPN2016290408","url":null,"abstract":"A case of psychogenic movement disorder mimicking acute cerebellar syndrome Psychogenic movement disorders (PMDs) are involuntary movements of various kinds without any underlying organic etiology. They can occur as tremor, spasm, dystonia, parkinsonism or myoclonus. A detailed history and neurological examination is essential to differentiate these disorders from organic neurological etiologies. Since PMDs are challenging entities in clinical practice, we presented this case of psychogenic tremor and gait disorder mimicking acute cerebellar syndrome in order to emphasize the importance of diagnostic clinical clues of PMDs in the differentiation of organic diseases, and to give","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"186 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132236236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Umut, B. Dernek, İlker Küçükparlak, T. Aydın, N. Karamustafalıoğlu, Fatma Nur Kesiktas
Acute psychotic attack under isoniazid treatment: a case report Isoniazid (isonicotinic acid hydrazide [INH]) has been used for treatment of tuberculosis since 1952. Pyridoxal5-phosphate and consequently GABA synthesis are decreased by INH, which increases cerebral excitability, and thus seizures might occure this way. In some rare cases, INH may induce mania, depression, obsessivecompulsive disorder, and psychosis via acting as a monoamine oxidase (MAO) inhibitor or by decreasing pyridoxine. In this report, a 28-year-old man with acute psychotic attack under prophylactic INH treatment before infliximab treatment, was presented.
{"title":"Acute Psychotic Attack under Isoniazid Treatment: a Case Report","authors":"G. Umut, B. Dernek, İlker Küçükparlak, T. Aydın, N. Karamustafalıoğlu, Fatma Nur Kesiktas","doi":"10.5350/DAJPN2016290411","DOIUrl":"https://doi.org/10.5350/DAJPN2016290411","url":null,"abstract":"Acute psychotic attack under isoniazid treatment: a case report Isoniazid (isonicotinic acid hydrazide [INH]) has been used for treatment of tuberculosis since 1952. Pyridoxal5-phosphate and consequently GABA synthesis are decreased by INH, which increases cerebral excitability, and thus seizures might occure this way. In some rare cases, INH may induce mania, depression, obsessivecompulsive disorder, and psychosis via acting as a monoamine oxidase (MAO) inhibitor or by decreasing pyridoxine. In this report, a 28-year-old man with acute psychotic attack under prophylactic INH treatment before infliximab treatment, was presented.","PeriodicalId":136580,"journal":{"name":"Düşünen Adam: The Journal of Psychiatry and Neurological Sciences","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2016-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130341583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：